Anna Lee Shares ASCO Study on Changes in Cancer Mortality Rates (VIDEO)

The investigational drug, called PMD-026, is currently in phase 2 clinical trials for the treatment of breast cancer.

In this month’s episode of Tuning In to the C-Suite, Briana Contreras, an editor of Managed Healthcare Executive, got to chatting with Sanjula Jain, Ph.D., chief research officer at Trilliant Health.

Gastric cancer, commonly known as stomach cancer, is the fifth most common cancer globally and the fifth leading cause of cancer-related deaths.

In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.

Time can be especially precious for people with advanced cancer. Researchers and clinicians are beginning to consider “time toxicity” as another aspect of treatment that burdens patients and their loved ones.

The speed of adoption of new practices in medicine is extremely slow. We need systems to test new protocols, make sure they’re safe and effective, and get them out into the world more rapidly.